0.45Open0.40Pre Close1 Volume418 Open Interest1.00Strike Price45.00Turnover293.18%IV22.99%PremiumAug 16, 2024Expiry Date0.18Intrinsic Value100Multiplier25DDays to Expiry0.27Extrinsic Value100Contract SizeAmericanOptions Type0.7384Delta0.3463Gamma2.48Leverage Ratio-0.0061Theta0.0003Rho1.83Eff Leverage0.0010Vega
Adaptimmune Therapeutics Stock Discussion
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
No comment yet